Keeping Up With the Treatment Landscape for MDD

The treatment landscape of major depression is increasingly shifting from monoaminergic agents to agents that modulate glutamate and GABA. Healthcare professionals need to stay up to date and educated on these changes in order to discuss the most current treatment options with their patients. In this podcast episode, we interview Dr Anita Clayton, a clinician researcher who has been involved in some of the clinical trials for these novel glutamatergic and GABAergic medications, and ask her key questions about mechanism of action and clinical application. Listeners will come away from this podcast episode more informed and more excited for the future of major depression care. 

Presenters:

Anita Clayton, MDDavid C. Wilson Professor and ChairDepartment of Psychiatry and Neurobehavioral SciencesProfessor of Clinical Obstetrics and GynecologyUniversity of Virginia School of MedicineCharlottesville, Virginia

This podcast episode is supported by an educational grant from Sage Therapeutics, Inc. and Biogen.

Link to full program:https://bit.ly/3YdPMPa